1Revier, CJ, Reininghaus, U, Dutta, R, Fearon, P, Murray, RM, Doody, GA, et al. Ten-year outcomes of first-episode psychoses in the MRC ÆSOP-10 study. J Nerv Ment Dis 2015; 203: 379.
2Lally, J, Ajnakina, O, Stubbs, B, Cullinane, M, Murphy, KC, Gaughran, F, et al. Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. Br J Psychiatry 2017; 211: 350–8.
3Zipursky, RB, Menezes, NM, Streiner, DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 2014; 152: 408–14.
4Alvarez-Jimenez, M, O'Donoghue, B, Thompson, A, Gleeson, JF, Bendall, S, Gonzalez-Blanch, C, et al. Beyond clinical remission in first episode psychosis: thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era. CNS Drugs 2016; 30: 357–68.
5Taylor, M, Jauhar, S. Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia. Ther Adv Psychopharmacol 2019; 9: 2045125319870033.
6Birchwood, M, Todd, P, Jackson, C. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry 1998; 172: 53–9.
7McGorry, PD, Killackey, E, Yung, A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 2008; 7: 148–56.
8Birchwood, M, MacMillan, F. Early intervention in schizophrenia. Aust N Z J Psychiatry 1993; 27: 374–8.
9Craig, TK, Garety, P, Power, P, Rahaman, N, Colbert, S, Fornells-Ambrojo, M, et al. The Lambeth Early Onset (LEO) team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ 2004; 329: 1067.
10Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481–5.
11Marwaha, S, Thompson, A, Upthegrove, R, Broome, MR. Fifteen years on–early intervention for a new generation. Br J Psychiatry 2016; 209: 186–8.
12Leucht, S, Davis, JM, Engel, RR, Kissling, W, Kane, JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009; 438: 7–14.
13Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96.
14Siskind, D, McCartney, L, Goldschlager, R, Kisely, S. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385–92.
15Thien, K, O'Donoghue, B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: a literature review. Early Interv Psychiatry 2019; 13: 18–23.
16Demjaha, A, Lappin, JM, Stahl, D, Patel, MX, MacCabe, JH, Howes, OD, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 2017; 47: 1981–9.
17Wheeler, AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 2008; 42: 852–60.
18Doyle, R, Behan, C, O'Keeffe, D, Masterson, S, Kinsella, A, Kelly, A, et al. Clozapine use in a cohort of first-episode psychosis. J Clin Psychopharmacol 2017; 37: 512–7.
19Birchwood, M, Lester, H, McCarthy, L, Jones, P, Fowler, D, Amos, T, et al. The UK national evaluation of the development and impact of early intervention services (the National EDEN studies): study rationale, design and baseline characteristics. Early Interv Psychiatry 2014; 8: 59–67.
20Kay, SR, Opler, LA, Lindenmayer, JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 1989; 155: 59–65.
21World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. World Health Organization, 1993.
22Andreasen, NC, Carpenter, WT, Kane, JM, Lasser, RA, Marder, SR, Weinberger, DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441–9.
23Suzuki, T, Remington, G, Mulsant, BH, Uchida, H, Rajji, TK, Graff-Guerrero, A, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res 2012; 197: 1–6.
24Amin, S, Singh, SP, Brewin, J, Jones, PB, Medley, I, Harrison, G. Diagnostic stability of first-episode psychosis: comparison of ICD–10 and DSM–III–R systems. Br J Psychiatry 1999; 175: 537–43.
27McGuffin, P, Farmer, A, Harvey, I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991; 48: 764–70.
28Lally, J, Ajnakina, O, Di Forti, M, Trotta, A, Demjaha, A, Kolliakou, A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med 2016; 46: 3231–40.
29Thompson, JV, Clark, JM, Legge, SE, Kadra, G, Downs, J, Walters, JT, et al. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. J Psychopharmacol 2016; 30: 436–43.
31Kendall, T, Hollis, C, Stafford, M, Taylor, C. Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance. BMJ 2013; 346: 150.
32Abdallah, N, Conn, R, Marini, AL. Improving physical health monitoring for patients with chronic mental health problems who receive antipsychotic medications. BMJ Open Qual 2016; 5: u210300.w4189.
33Kahn, RS, Winter van Rossum, I, Leucht, S, McGuire, P, Lewis, SW, Leboyer, M, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 2018; 5: 797–807.
34Buchanan, RW, Kreyenbuhl, J, Kelly, DL, Noel, JM, Boggs, DL, Fischer, BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71–93.
35Tungaraza, TE, Farooq, S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol 2015; 5: 88–96.
36Joint Formulary Committee. BNF 76 (British National Formulary). Pharmaceutical Press, 2018.
37Taipale, H, Tanskanen, A, Mehtälä, J, Vattulainen, P, Correll, CU, Tiihonen, J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020; 19: 61–8.
38Gee, S, Vergunst, F, Howes, O, Taylor, D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014; 130: 16–24.
39Gee, SH, Shergill, SS, Taylor, DM. Patient attitudes to clozapine initiation. Int Clin Psychopharmacol 2017; 32: 337–42.
40Beck, K, McCutcheon, R, Bloomfield, M, Gaughran, F, Marques, T, Maccabe, J, et al. The practical management of refractory schizophrenia - the Maudsley Treatment Review and Assessment Team service approach. Acta Psychiatr Scand 2014; 130: 427–38.
42Lieberman, JA, Phillips, M, Gu, H, Stroup, S, Zhang, P, Kong, L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995.
43Girgis, RR, Phillips, MR, Li, X, Li, K, Jiang, H, Wu, C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry 2011; 199: 281–8.
44Sanz-Fuentenebro, J, Taboada, D, Palomo, T, Aragües, M, Ovejero, S, Del Alamo, C, et al. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. Schizophr Res 2013; 149: 156–61.
45Agid, O, Remington, G, Kapur, S, Arenovich, T, Zipursky, RB. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007; 27: 369–73.
46Yoshimura, B, Yada, Y, So, R, Takaki, M, Yamada, N. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res 2017; 250: 65–70.
47Remington, G, Agid, O, Foussias, G, Hahn, M, Rao, N, Sinyor, M. Clozapine‘s role in the treatment of first-episode schizophrenia. Am J Psychiatry 2013; 170: 146–51.